145 related articles for article (PubMed ID: 30396925)
41. In vivo cleaved CDCP1 promotes early tumor dissemination via complexing with activated β1 integrin and induction of FAK/PI3K/Akt motility signaling.
Casar B; Rimann I; Kato H; Shattil SJ; Quigley JP; Deryugina EI
Oncogene; 2014 Jan; 33(2):255-68. PubMed ID: 23208492
[TBL] [Abstract][Full Text] [Related]
42. Targeting CUB domain-containing protein 1 with a monoclonal antibody inhibits metastasis in a prostate cancer model.
Siva AC; Wild MA; Kirkland RE; Nolan MJ; Lin B; Maruyama T; Yantiri-Wernimont F; Frederickson S; Bowdish KS; Xin H
Cancer Res; 2008 May; 68(10):3759-66. PubMed ID: 18483259
[TBL] [Abstract][Full Text] [Related]
43. Comparative proteomic analysis of two stress-management strategies in pancreatic cancer.
Baron B; Fujioka T; Kitagawa T; Maehara S; Maehara Y; Nakamura K; Kuramitsu Y
Cancer Genomics Proteomics; 2015; 12(2):83-7. PubMed ID: 25770192
[TBL] [Abstract][Full Text] [Related]
44. Ratio of phosphorylated HSP27 to nonphosphorylated HSP27 biphasically acts as a determinant of cellular fate in gemcitabine-resistant pancreatic cancer cells.
Kang D; Choi HJ; Kang S; Kim SY; Hwang YS; Je S; Han Z; Kim JH; Song JJ
Cell Signal; 2015 Apr; 27(4):807-17. PubMed ID: 25615626
[TBL] [Abstract][Full Text] [Related]
45. CDCP1 regulates the function of MT1-MMP and invadopodia-mediated invasion of cancer cells.
Miyazawa Y; Uekita T; Ito Y; Seiki M; Yamaguchi H; Sakai R
Mol Cancer Res; 2013 Jun; 11(6):628-37. PubMed ID: 23439492
[TBL] [Abstract][Full Text] [Related]
46. Theranostic Targeting of CUB Domain Containing Protein 1 (CDCP1) in Pancreatic Cancer.
Moroz A; Wang YH; Sharib JM; Wei J; Zhao N; Huang Y; Chen Z; Martinko AJ; Zhuo J; Lim SA; Zhang LH; Seo Y; Carlin S; Leung KK; Collisson EA; Kirkwood KS; Wells JA; Evans MJ
Clin Cancer Res; 2020 Jul; 26(14):3608-3615. PubMed ID: 32341034
[TBL] [Abstract][Full Text] [Related]
47. Subtractive immunization using highly metastatic human tumor cells identifies SIMA135/CDCP1, a 135 kDa cell surface phosphorylated glycoprotein antigen.
Hooper JD; Zijlstra A; Aimes RT; Liang H; Claassen GF; Tarin D; Testa JE; Quigley JP
Oncogene; 2003 Mar; 22(12):1783-94. PubMed ID: 12660814
[TBL] [Abstract][Full Text] [Related]
48. Active Hexose Correlated Compound (AHCC) Inhibits the Proliferation of Ovarian Cancer Cells by Suppressing Signal Transducer and Activator of Transcription 3 (STAT3) Activation.
Choi JY; Lee S; Yun SM; Suh DH; Kim K; No JH; Jeong EH; Kim YB
Nutr Cancer; 2018 Jan; 70(1):109-115. PubMed ID: 29111786
[TBL] [Abstract][Full Text] [Related]
49. Cell line and patient-derived xenograft models reveal elevated CDCP1 as a target in high-grade serous ovarian cancer.
Harrington BS; He Y; Davies CM; Wallace SJ; Adams MN; Beaven EA; Roche DK; Kennedy C; Chetty NP; Crandon AJ; Flatley C; Oliveira NB; Shannon CM; deFazio A; Tinker AV; Gilks CB; Gabrielli B; Brennan DJ; Coward JI; Armes JE; Perrin LC; Hooper JD
Br J Cancer; 2016 Feb; 114(4):417-26. PubMed ID: 26882065
[TBL] [Abstract][Full Text] [Related]
50. CUB Domain-Containing Protein 1 (CDCP1) is a rational target for the development of imaging tracers and antibody-drug conjugates for cancer detection and therapy.
Khan T; Lyons NJ; Gough M; Kwah KKX; Cuda TJ; Snell CE; Tse BW; Sokolowski KA; Pearce LA; Adams TE; Rose SE; Puttick S; Pajic M; Adams MN; He Y; Hooper JD; Kryza T
Theranostics; 2022; 12(16):6915-6930. PubMed ID: 36276654
[No Abstract] [Full Text] [Related]
51. Targeting a proteolytic neoepitope on CUB domain containing protein 1 (CDCP1) for RAS-driven cancers.
Lim SA; Zhou J; Martinko AJ; Wang YH; Filippova EV; Steri V; Wang D; Remesh SG; Liu J; Hann B; Kossiakoff AA; Evans MJ; Leung KK; Wells JA
J Clin Invest; 2022 Feb; 132(4):. PubMed ID: 35166238
[TBL] [Abstract][Full Text] [Related]
52. Cellular settings mediating Src Substrate switching between focal adhesion kinase tyrosine 861 and CUB-domain-containing protein 1 (CDCP1) tyrosine 734.
Wortmann A; He Y; Christensen ME; Linn M; Lumley JW; Pollock PM; Waterhouse NJ; Hooper JD
J Biol Chem; 2011 Dec; 286(49):42303-42315. PubMed ID: 21994943
[TBL] [Abstract][Full Text] [Related]
53. Proteolysis-induced N-terminal ectodomain shedding of the integral membrane glycoprotein CUB domain-containing protein 1 (CDCP1) is accompanied by tyrosine phosphorylation of its C-terminal domain and recruitment of Src and PKCdelta.
He Y; Wortmann A; Burke LJ; Reid JC; Adams MN; Abdul-Jabbar I; Quigley JP; Leduc R; Kirchhofer D; Hooper JD
J Biol Chem; 2010 Aug; 285(34):26162-73. PubMed ID: 20551327
[TBL] [Abstract][Full Text] [Related]
54. Theranostic Targeting of CUB Domain Containing Protein 1 (CDCP1) in Pancreatic Cancer-Letter.
Birnbaum DJ; Finetti P; Birnbaum D; Bertucci F
Clin Cancer Res; 2020 Oct; 26(20):5539. PubMed ID: 33060289
[No Abstract] [Full Text] [Related]
55. Cyclopamine reverts acquired chemoresistance and down-regulates cancer stem cell markers in pancreatic cancer cell lines.
Yao J; An Y; Wie JS; Ji ZL; Lu ZP; Wu JL; Jiang KR; Chen P; Xu ZK; Miao Y
Swiss Med Wkly; 2011; 141():w13208. PubMed ID: 21630164
[TBL] [Abstract][Full Text] [Related]
56. Elevated CDCP1 predicts poor patient outcome and mediates ovarian clear cell carcinoma by promoting tumor spheroid formation, cell migration and chemoresistance.
He Y; Wu AC; Harrington BS; Davies CM; Wallace SJ; Adams MN; Palmer JS; Roche DK; Hollier BG; Westbrook TF; Hamidi H; Konecny GE; Winterhoff B; Chetty NP; Crandon AJ; Oliveira NB; Shannon CM; Tinker AV; Gilks CB; Coward JI; Lumley JW; Perrin LC; Armes JE; Hooper JD
Oncogene; 2016 Jan; 35(4):468-78. PubMed ID: 25893298
[TBL] [Abstract][Full Text] [Related]
57. Identification of CDCP1 as a hypoxia-inducible factor 2α (HIF-2α) target gene that is associated with survival in clear cell renal cell carcinoma patients.
Emerling BM; Benes CH; Poulogiannis G; Bell EL; Courtney K; Liu H; Choo-Wing R; Bellinger G; Tsukazawa KS; Brown V; Signoretti S; Soltoff SP; Cantley LC
Proc Natl Acad Sci U S A; 2013 Feb; 110(9):3483-8. PubMed ID: 23378636
[TBL] [Abstract][Full Text] [Related]
58. Resistance to gemcitabine in the pancreatic cancer cell line KLM1-R reversed by metformin action.
Baron B; Wang Y; Maehara S; Maehara Y; Kuramitsu Y; Nakamura K
Anticancer Res; 2015 Apr; 35(4):1941-9. PubMed ID: 25862846
[TBL] [Abstract][Full Text] [Related]
59. TIMP1 down-regulation enhances gemcitabine sensitivity and reverses chemoresistance in pancreatic cancer.
Tan Y; Li X; Tian Z; Chen S; Zou J; Lian G; Chen S; Huang K; Chen Y
Biochem Pharmacol; 2021 Jul; 189():114085. PubMed ID: 32522594
[TBL] [Abstract][Full Text] [Related]
60. Roles of CUB domain-containing protein 1 signaling in cancer invasion and metastasis.
Uekita T; Sakai R
Cancer Sci; 2011 Nov; 102(11):1943-8. PubMed ID: 21812858
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
